Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, 80131 Naples, Italy.
Department of Public Health, University of Naples Federico II, Naples (NA), Italy.
Crit Rev Oncol Hematol. 2024 Feb;194:104263. doi: 10.1016/j.critrevonc.2024.104263. Epub 2024 Jan 11.
The clinical implementation of liquid biopsy has dramatically modified the analytical paradigm for several solid tumors. To date, however, only circulating free DNA (cfDNA) has been approved in clinical practice to select targeted treatments for patients with colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and breast cancer (BC). Interestingly, emerging liquid biopsy analytes in peripheral blood, including circulating tumor cells (CTC), miRNA, and extracellular vesicles (EVs), have been shown to play a crucial role in the clinical management of solid tumor patients. Here, we review how these blood-based biomarkers may positively impact early diagnosis, prognosis, and treatment response in ovarian cancer (OC) patients.
液体活检的临床应用极大地改变了几种实体瘤的分析模式。然而，迄今为止，只有循环游离 DNA（cfDNA）在临床上被批准用于选择结直肠癌（CRC）、非小细胞肺癌（NSCLC）和乳腺癌（BC）患者的靶向治疗。有趣的是，外周血中新兴的液体活检分析物，包括循环肿瘤细胞（CTC）、miRNA 和细胞外囊泡（EVs），已被证明在实体瘤患者的临床管理中发挥着至关重要的作用。在这里，我们综述了这些基于血液的生物标志物如何对卵巢癌（OC）患者的早期诊断、预后和治疗反应产生积极影响。
